ROS1 and non-small cell lung carcinoma: The clinical value of proto‐oncogene 1 (ROS1)‐directed TKIs was first prospectively explored in NSCLC patients, and in 2016, the FDA and EMA approved crizotinib for the treatment of advanced‐stage ROS1‐rearranged NSCLC.182